Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGC20-1259 in mild to moderate Alzheimer's disease
2008-003659-63Phase 2Terminated
- Sponsor
- BTG
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGC20-1259 in Alzheimer's disease (AD) (4 arms), sponsored by BTG. Primary endpoint: Primary efficacy endpoint. Started Aug 2008; status: terminated.
02
Drugs
BGC20-1259
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-003659-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003659-63.